A high prevalence of renal hypouricemia caused by inactive SLC22A12 in Japanese  by Iwai, Naoharu et al.
Kidney International, Vol. 66 (2004), pp. 935–944
GENETIC DISORDERS – DEVELOPMENT
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A high prevalence of renal hypouricemia caused by inactive
SLC22A12 in Japanese.
Background. Recently, SLC22A12 has been identified as a
urate-anion exchanger in the human kidney.
Methods. We screened for polymorphisms of SLC22A12 and
conducted an association study between genetic polymorphisms
and urate levels in an epidemiologic cohort representing the
general population in Japan. Functional significance of muta-
tions was assessed by oocyte expression analysis.
Results. We found five missense, one nonsense, and one
deletion mutations [R90H, A226V, R228E, W258Stop, Q312L,
D313A (deletion of 313D-333P), and R477H] in 24 subjects with
hypouricemia recruited from an epidemiologic cohort (Suita
Study) representing the general population in Japan (N = 1875).
A statistical analysis indicated that the 90H (N = 14), 477H
(N = 5), and 258Stop (hetero + homo N = 82 + 3) alleles were
associated with hypouricemia. The alleles 228E and 313A (dele-
tion of 313D-333P) were found just once in the total population.
In vitro oocyte expression analysis indicated that 313A (dele-
tion of 313D-333P) had no urate transport activity, indicating
that this is a newly identified mutation for idiopathic renal hy-
pouricemia. Intriguingly, the allele frequency of 258Stop was
unexpectedly high (2.37%). However, this inactivating muta-
tion does not seem to be harmful in the general population.
The effects of common polymorphisms of SLC22A12 were also
investigated. Based on linkage disequilibrium, 16 common poly-
morphisms were categorized into six distinct groups, and six
representative genotypes were determined. None of these six
common polymorphisms affected the serum uric acid level. A
haplotype analysis also suggested that these common geno-
types/haplotypes were not important in determining the serum
uric acid levels in the general population.
Conclusion. SLC22A12 is a major gene for hypouricemia but
not hyperuricemia in Japanese.
Urate is present in blood at higher levels in human
blood than in other mammals, since humans have an ef-
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fective renal urate reabsorption system despite the loss
of hepatic uricase through evolutionary mutation [1]. Re-
cently, SLC22A12 has been identified as a urate-anion
exchanger in the human kidney [2]. Inactivating muta-
tions in SLC22A12 have been shown to cause renal id-
iopathic hypouricemia [2]. It is possible that common
genetic variants of SLC22A12 may influence urate levels
in the general population and may contribute to hyper- or
hypouricemia. In the present study, we screened for poly-
morphisms of SLC22A12 and conducted an association
study between genetic polymorphisms and urate levels
using an epidemiologic cohort representing the general
population in Japan.
METHODS
Study population and DNA analysis
We screened for genetic polymorphisms in SLC22A12
by sequencing the promoter regions (up to −2.0 kb) and
all of the exons. We selected 93 healthy subjects (uric
acid levels between 3 mg/dL and 8 mg/dL), 24 subjects
with hypouricemia, and 36 subjects with hyperuricemia
from among 1875 consecutive subjects recruited from the
Suita Study. Since the uric acid level is influenced by many
environmental factors, including gender, age, body mass
index (BMI), plasma creatinine level, and alcohol con-
sumption, we calculated residuals of uric acid levels by ad-
justing for the above-mentioned environmental factors.
We selected the top 36 subjects with high residual values
(above +2.1 mg/dL) as hyperuricemic subjects and the
bottom 24 subjects with low residual values (below −2.1
mg/dL) as hypouricemic subjects. The selection criteria
and design of the Suita Study have been described previ-
ously [3]. Briefly, the sample consisted of 14,200 men and
women (30 to 79 years of age), stratified by gender and
10-year age groups who had been randomly selected from
the municipal population registry. They were all invited
by letter to attend regular cycles of follow-up examina-
tion (every 2 years). We routinely check 10 to 15 partici-
pants per day. DNA from leukocytes was collected from
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Table 1. Primers for sequencing
Primer sequence
Region Sense Antisense
Promoter 1 5′-CCAGACTACCAGGAGCTCACTGG-3′ 5′CAATGCCACCCTGAGATCTCTGTC-3′
Promoter 2 5′-CACACCCTGCATCAGCACACAC-3′ 5′-GCTGAGAGGCTCGAGAGTGAGTG-3′
Exon 1 5′-GCTGGAGAAGCCACTGTGGGCAC-3′ 5′-GCTGAGAGGCTCGAGAGTGAGTG-3′
Exon 2 5′-CTCACTGTTCCACAGGGTCTTGCTCT-3′ 5′-GTTCCAGACCTCCCTACCTGGCAC-3′
Exon 3-Exon 4 5′-CTCAGCTCAGCGGGCAAGCATAGG-3′ 5′-CAAGCCCTGGTTGAAGTGGGTGTC-3′
Exon 5-Exon 6 5′-GTTCCACAGAGTCATCCCTCCCTCC-3′ 5′-CAGGGGATTTCTGCCTCCCTCTCTG-3′
Exon 7 5′-CTGGGAAGAAGGTCTCAGAGAGGAGGAG 5′-GAAGAGCTCGCTGCTGTAGATGGTGAT
Exon 8-Exon 9 5′-CACTCAGGACAGGATACCCAGATG-3′ 5′-GTTGCCACTCTCCCAGAGATGTAC-3′
Exon 10 5′-CATCACATGCTCGGGAGCTCAGTTC-3′ 5′-CAGGGTGATGGTGCACTGGGTCAC-3′
5′-5′-CTCGTGGCTTCGGAGAGC-3′ 5′-GTCAAGCAGAGGGTTGGCA-3-3′
The indicated regions were amplified by the primers listed in the Table.
participants who visited the National Cardiovascular
Center between April 2002 and February 2003. All of the
participants were Japanese, and only those who gave their
written informed consent for genetic analyses of cardio-
vascular diseases were included. The ethics committee of
the National Cardiovascular Center approved the study
protocol.
Primer sequences are shown in Table 1. The geno-
type was determined by the TaqMan method (http://www.
appliedbiosystems.com/) in 1875 consecutive subjects.
Uric acid levels were determined using a kit (enzyme
method, Uricolor-liquid; Ono Pharmaceutical Co., Ltd.,
Osaka, Japan).
Statistical analysis
Values are expressed as mean ± SD. All statistical anal-
yses were performed with the JMP statistical package and
StatView 5.0 (SAS Institute, Inc., Cary, NC, USA). Mul-
tiple regression analyses indicated that the uric acid level
was determined by gender, BMI, age, plasma creatinine,
and alcohol consumption (ethanol g/day). The relation-
ships between genotypes and uric acid levels were an-
alyzed by one-way analysis of variance (ANOVA) and
the Kruskal-Wallis test with the Bonferroni correction.
A subject was categorized as having hyperuricemia when
the subject was being treated with hypouricemic drugs or
had a uric acid level higher than 7.0 mg/dL.
Linkage disequilibriums (R2 values) between poly-
morphisms and estimation of haplotypes were calcu-
lated using the SNPAlyze statistical package (Dynacom,
Kanagawa, Japan).
Functional analysis of SLC22A12 mutants
Missense and deletion mutants were constructed with
the QuickChange site-directed mutagenesis kit (Strata-
gene, La Jolla, CA, USA). Proper construction of the mu-
tated cDNA was confirmed by sequencing. Mutant cRNA
was synthesized using an mMESSAGE mMACHINE kit
(Ambion, Inc., Austin, TX, USA). The injection of 50 ng
of cRNA into Xenopus laevis oocytes, and maintenance
of the oocytes and uptake studies of 14C-urate were per-
formed as described previously [4].
RESULTS
Sequence analysis of SLC22A12
Of the total 1875 consecutive subjects, 50 had hy-
pouricemia (<3.0 mg/dL) and 56 had hyperuricemia
(>8.0 mg/dL). We selected 93 healthy subjects, 24 with
hypouricemia (<3 mg/dL), and 36 with hyperuricemia
(>8 mg/dL) for sequence analysis. Sequence analysis of
SLC22A12 in the 93 healthy subjects revealed eight poly-
morphisms in the promoter region and 20 polymorphisms
in exonic regions (Fig. 1 and Table 2). Sequence analysis
in 24 subjects with hypouricemia revealed seven addi-
tional missense mutations (Figs. 1 to 3, Table 2): R90H,
A226V, R228E, W258Stop, Q312L, D313A (deletion of
313D-333P), and R477H. Intriguingly, we found 11 het-
erozygotes and two homozygotes for 258Stop among the
24 subjects with hypouricemia selected for sequence anal-
yses (Table 2). Sequence analysis in the 36 subjects with
hyperuricemia revealed no additional polymorphisms
compared to those found in the 93 healthy subjects.
Association study with missense mutations
All of the missense and nonsense mutations were
detected in the subjects with hypouricemia (Table 2).
To confirm whether these mutations contribute to hy-
pouricemia, the effects of these mutations on the uric
acid level were first investigated by an association study.
Table 3 shows the probes and primers for TaqMan.
The minor allele frequencies of A226V, R228E, and
D313A (deletion of 313D-333P) were very low; only one
allele in the total population (1875 subjects or 3750 alle-
les). Therefore, we cannot conclude whether these mu-
tations actually contribute to hypouricemia based on a
statistical analysis.
The 226V mutation was detected in a subject homozy-
gous for the 258X allele. Thus, the hypouricemia in this
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Fig. 1. Polymorphisms of SLC22A12. The
sites for polymorphisms are shown on the
SLC22A12 gene scheme. The arrows indicate
the site of polymorphisms. The numbers of
the polymorphic sites correspond to those in
Table 2. Boxes indicate exons.
subject can be explained by this homozygosity of the
258X allele. Moreover, since alanine and valine are both
hydrophobic amino acids, this homologous substitution
would not seem to alter the function of URAT1.
The R228E missense mutation was tested with regard
to urate transport activity by in vitro expression analy-
sis in Xenopus oocytes. As shown in Figure 4, the urate
transport activity of SLC22A12 with 228E was not sig-
nificantly less than that of the wild type. Although it is
possible that this mutation might be in tight linkage dise-
quilibrium with some other unidentified mutation that
reduces the SLC22A12 expression level, we could
not confirm that this mutation was responsible for
hypouricemia.
On the other hand, the urate transport activity of
SLC22A12 with 313A (deletion of 313D-333P) was sig-
nificantly less than that of the wild type (Fig. 4). Thus,
this is a newly identified mutation responsible for renal
idiopathic hypouricemia in Japanese.
The Q312L mutation was detected in two subjects. One
subject had one 312L+313A (deletion type) allele and
had hypouricemia. The other had one 312L+313D (wild
type) allele and a serum uric acid level of 5.5 mg/dL. Thus,
the Q312L mutation seems to be neutral.
Subjects who were heterozygous for R90H (14 sub-
jects) had significantly lower residuals of serum uric acid
levels than those with the wild-type genotype (P < 0.0004,
Kruskal-Wallis analysis followed by the Bonferroni cor-
rection). This R90H missense mutation has been previ-
ously reported in renal hypouricemic patients recruited
from Jikei and Tottori University Hospitals who were dif-
ferent from our subjects with the 90H mutation [4]. The
urate transport activity of SLC22A12 with the 90H muta-
tion has been reported to be significantly less than that of
the wild type [4]. The allele frequency of 90H was 0.4%.
Subjects who were heterozygous for R477H (five sub-
jects) had significantly lower residuals of serum uric
acid levels that those with the wild-type genotype (P <
0.0024, Kruskal-Wallis analysis followed by the Bonfer-
roni correction). However, the urate transport activity
of SLC22A12 with 477H was not significantly less than
that of the wild type (Fig. 4). This discrepancy might be
explained by the hypothesis that some other unidentified
mutations in tight linkage disequilibrium with the R477H
mutation could reduce the expression level of SLC22A12.
Another possibility is that the discrepancy between the
statistical data and the functional analysis regarding the
R477H mutation may reflect some limitation of the
Xenopus oocyte expression system. This amino acid re-
placement might alter the processing of the transporter
in mammalian cells. Additional studies will be needed to
clarify this point. Further studies will be necessary to con-
firm these hypotheses. The allele frequency of 477H was
0.13%.
The W258Stop mutation has been reported previously,
and the truncated transporter has been shown to have
no transporter activity [2]. Subjects heterozygous or ho-
mozygous for this mutation had significantly lower resid-
uals of serum uric acid levels than those with the wild-type
genotype (P < 0.0005, respectively, Kruskal-Wallis analy-
sis followed by the Bonferroni correction). We found one
subject with possibly compound heterozygous mutations
(258Stop and 90H) whose uric acid level was similar to
that in subjects who were homozygous for the 258Stop
allele (Table 4). One of the interesting findings in the
present study is that this mutation occurs at a very high
frequency among Japanese. We found 83 heterozygotes
(including one compound heterozygote) and three ho-
mozygotes among 1875 subjects. The allele frequency of
258Stop was calculated to be 2.37%.
Other phenotypes and SLC22A12 mutations
Uric acid has been recognized to have several direct
biologic functions. Thus, various phenotypes were com-
pared in subjects with and without these mutations. As
shown in Table 4, there were no significant differences
in the incidence of hypertension, plasma creatinine level,
age, or BMI between the two groups.
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A 226 V
R 228 E
Deletion (313~333)
Q 312 L R 477 H
R 90 H W 258 Stop
Fig. 2. Mutations in SLC22A12. The sites for missense or nonsense
mutations are shown on the predicted protein structure of the uric acid-
anion transporter. Numbers 1–12 indicate transmembrane domains.
Association study with common polymorphisms
The effects of common polymorphisms of SLC22A12
were also investigated. None of these polymorphisms af-
fected the amino acid sequence of SLC22A12. Based
on linkage disequilibrium, common polymorphisms were
categorized into six distinct groups (Table 5), and repre-
sentative genotypes in each of the six groups were deter-
mined. Since the R90H, D313A, R477H, and W258Stop
mutations all strongly affected uric acid levels, subjects
with these mutations were excluded from the following
association studies (N = 1708).
Table 6 shows the effects of common polymorphisms
on residuals of the uric acid level. None of these six poly-
morphisms affected serum uric acid levels. We corrected
P values using the Bonferroni method (Pc) by multiplying
by 6 (number of polymorphisms analyzed).
The standard deviation of the residuals of the serum
uric acid level was 1.0 (Table 6). The total sample size
was about 1700. If a subgroup comprised 10% of the to-
tal population, we should be able to detect a difference
between mean values of 0.3 mg/dL with a statistical power
of 0.87 (alfa = 0.010, two-tailed). Thus, we can conclude
that common polymorphisms of SLC22A12 do not influ-
ence residuals of the uric acid level by at least 0.3 mg/dL.
We constructed haplotypes defined by the C(–1957)T,
W258Stop, and G9463 genotypes, and compared the fre-
quencies of the haplotypes between subjects with normal
serum uric acid levels (<7.0 mg/dL, N = 1597) and sub-
jects with hyperuricemia (≥7.0 mg/dL and/or treatment
with hypouricemic drugs, N = 256). We selected the C(–
1957)T and G9453 genotypes because these genotype had
marginal effects on uric acid levels by a simple ANOVA
analysis (Table 6). In this haplotype analysis, we excluded
subjects with R90H, D313A, or R477H, since the allele
frequencies of these genotype were very low. As shown
in Table 7, the frequency of the haplotype (111) was sig-
nificantly higher in subjects with normal serum uric acid
levels than in those with hyperuricemia. This haplotype
(111) corresponded to the allele 258Stop. However, no
significant differences were observed in the frequencies
of other haplotypes between the two groups, which sug-
gests that common polymorphisms did not influence uric
acid levels.
DISCUSSION
In the present study, we identified six missense mu-
tations and one nonsense mutation in SLC22A12 in 24
subjects with hypouricemia selected from the total 1875
subjects recruited from the Suita Study. The allele fre-
quencies of 90H and 258Stop, which have been shown
to contribute to renal hypouricemia in other hospital-
based study populations-[2, 4], were 0.40% and 2.37%,
respectively. The present epidemiologic study showed
that the prevalence of these inactive SLC22A12 muta-
tions was unexpectedly high in Japanese. We also demon-
strated, based on an in vitro expression analysis with
Xenopus oocytes, that the newly identified D313A (dele-
tion of 313D-333P) mutation caused renal hypouricemia
in Japanese. We then investigated the effects of common
polymorphisms of SLC22A12 on serum uric acid levels.
None of the common polymorphisms seemed to affect
serum uric acid levels.
Many studies have found that uric acid is not an in-
dependent risk factor for cardiovascular diseases after
controlling for other risk factors [5–8]. The uric acid level
is higher in men and postmenopausal women because
estrogen is uricosuric [9]. Obesity often accompanies hy-
peruricemia because insulin stimulates sodium and urate
reabsorption in the proximal tubule [9]. Uric acid is ele-
vated in subjects with renal diseases as a result of reduced
glomerular filtration rate and urate excretion. Alcohol in-
take results in elevated uric acid levels due to increased
generation and decreased excretion [10]. Since the uric
acid level is influenced by the above-mentioned cardio-
vascular risk factors, it has been considered to be simply
a marker for cardiovascular diseases. However, uric acid
has also been recognized to be more than simply an inert
bystander and indeed to have several important biologic
functions that could be either beneficial or harmful to
humans.
Ames et al [11] hypothesized that uric acid provides
an antioxidant defense in humans against oxidant- and
radical-causing aging and cancer. Uric acid seems to
be one of the most important antioxidants in human
plasma [11–13]. A positive correlation has been reported
between uric acid levels and life span in primates [14].
However, in the present study, the mean age of subjects
with inactive SLC22A12 alleles was not significantly dif-
ferent from that of subjects without inactive SLC22A12
alleles. The allele frequency of 258Stop in subjects
940 Iwai et al: Renal hypouricemia caused by inactive SLC22A12 in Japanese
TCA GGT CCGCCG/A TTCCGCCAG
Q C R R/H
C
R 90 H
F R Q
ACG GGC GC ACG/A GCCCGACCC
T A A R/E
G
R 228 E
A R P
CCG GAG AGGTG/A CCGACGGTA
A G G R/H
C
R 477 H
A A M
CGT TCG CAC AA G CAGGG CGT
L L T Stop
T
W 258 Stop
D R
C TTTC AGCC AT CG GG AG G AG GC TGAG CAT GG GCC AGCCTCCT G CCAGCCTG
L S A M R E E L S M G Q P P A S L
CCCACC AAGG ACC TCAGC TCCC TG GG AAGAAGG TC TCAGAG AGGAGGAGGTGCC TGGCGCCCCCAG TGCCAACAGCACCC ACCCCCGCC TCCACA G GTC TTG
Exon 6
AAGGGGCA GTGCAGGACACCCTGA CCCCT GAGGTAAGGCT GGGT CCT CCT CAAACCCGGA CCCT CAGACCCTCT CCCTGCCCCT GCA TAGGGCACCCT GGGA GA
K G A V Q D T L T P E
V L
Exon 5
A A G G G G G C A G T G C T G G C T C C T G C C A G C C T G
K G A V L A P A S L
Deletion type
Wild type
Deletion (313~333)
Fig. 3. Sequences for missense mutations. The sequences around the missense mutations (R90H, R228E, D313A, and R477H) and the nonsense
mutation (W258Stop) are shown. The arrows indicate the sites of mutations.
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Fig. 4. Urate transport ability of the SLC22A12 mutants. Urate uptake
by the oocyte injected with the 313A (deletion of 313D-333P) mutant
cRNA was significantly less than that with the wild-type cRNA (P <
0.01 vs. wild-type). Urate uptake by the oocyte injected with the 228E or
477H cRNA was not significantly different from that with the wild-type
cRNA. Statistical analysis was performed with Tukey-Kramer’s HSD
test. Vertical bar indicates standard deviation (N = 8).
Table 6. Effects of common polymorphisms of SLC22A12 on the
residuals of uric acid levels
AA Aa aa P value Pc
C(-1957)T 0.0 (1.0) 0.0 (1.0) 0.3 (0.9) 0.0823 0.4938
(1188) (465) (55)
A(-1821)G 0.0 (1.0) 0.0 (0.9) −0.1 (1.0) 0.7545 1.0000
(1169) (493) (46)
C246T 0.0 (1.0) 0.0 (1.0) 0.0 (1.1) 0.9965 1.0000
(929) (657) (122)
G6948A 0.0 (1.0) 0.0 (1.0) 0.0 (1.0) 0.5437 1.0000
(920) (672) (387)
G7752A −0.1 (1.0) 0.0 (1.0) 0.1 (1.0) 0.1560 0.936
(442) (879) (387)
G9463- 0.1 (1.0) 0.0 (1.0) −1.0 (1.0) 0.0502 0.3012
(578) (736) (394)
Values are mean(SD). The number of subjects is indicated in parentheses. AA,
Aa, and aa indicate major homozygotes, heterozygotes, and minor homozygotes.
P values are corrected by the Bonferroni method (Pc).
<75 years (2.30%) was not significantly different from
that in subjects ≥75 years (2.67%). The genotype fre-
quencies did not deviate from Hardy-Weinberg equilib-
rium. Since subjects with inactive SLC22A12 alleles have
a low uric acid level throughout their life span, low uric
acid levels may not be associated with reduced longevity.
Higher uric acid levels may contribute to endothelial
dysfunction. Serum uric acid and nitric oxide levels have
been reported to vary during the day in a reciprocal man-
ner [15]. Waring et al [16] reported that uric acid infusion
resulted in impaired acetylcholine-induced vasodilation
in the forearm. Thus, hyperuricemia itself may lead to
cardiovascular diseases, including hypertension and is-
chemic heart diseases. If so, inactive SLC22A12 alleles
might protect against hypertension and ischemic heart
diseases. However, as shown in the present study, inac-
tive SLC22A12 alleles were not associated with a reduced
Table 7. Haplotype analysis
Fr in N Fr in HU
Haplotype Fr (N = 1597) (N = 256) P value Pc
000 43.01 43.14 42.19 0.6849 1.0000
001 37.88 37.60 39.65 0.3766 1.0000
101 16.65 16.44 17.99 0.3918 1.0000
111 2.37 2.72 0.2 <0.0001 <0.0005
100 0.08 0.09 0.00 0.3448 1.0000
Haplotype is constructed with C(-1957)T, W258Stop, and G9463-genotypes.
Major allele is indicated as “0” and minor allele is indicated as “1.” The
differences in frequencies (Fr) of haplotypes are compared between subjects
with normal serum uric acid levels (N) and those with hyperuricemia (HU). The
definition of HU is described in the text. P values are calculated by chi-square
analysis, and are corrected by the Bonferroni method (multiplying the number
of comparison = 5). The frequencies of the haplotypes (110, 011, and 010) have
been calculated to be very low (<0.1%) in Japanese and are not included in
Table 7.
incidence of hypertension. Our preliminary analysis in-
dicated that the frequency of the 258Stop allele in 516
subjects with myocardial infarction (1.84%) was not sig-
nificantly different from that in the general population
(2.46%). Again, inactive SLC22A12 alleles seem to be
neutral.
The unexpectedly high prevalence (∼3%) of inac-
tive SLC22A12 alleles suggests that at least these mu-
tations may not be harmful to humans. Idiopathic re-
nal hypouricemia has been reported to be associated
with exercise-induced acute renal failure [17], and this
nephropathy may be a possible major adverse influence
of inactive SLC22A12 mutations. However, subjects with
inactive SLC22A12 alleles had normal creatinine levels.
We found four homozygotes with inactive SLC22A12 al-
leles (the expected number was 1), and these four sub-
jects also had normal creatinine levels. Since renal func-
tion, except for urine-concentrating ability, recovered af-
ter exercise-induced acute renal failure in hypouricemic
subjects, more thorough characterization of subjects with
inactive SLC22A12 will be necessary to assess the inci-
dence of this nephropathy. Since the Suita study princi-
pally involves general health checkups, it might be dif-
ficult to conduct more specific research-oriented labora-
tory and physiologic tests. This drawback of the present
epidemiologic study could perhaps be offset by patient-
oriented clinical studies. However, an unexpectedly high
prevalence of SLC22A12 inactive mutations in Japanese
could only be clarified by epidemiologic studies.
Eight of our 1875 subjects had uric acid levels below
2.0 mg/dL. Of these eight subjects, four were homozy-
gous [three homozygotes (258Stop) and one compound
heterozygote (258Stop+90H)], and two were heterozy-
gous (258Stop) for the inactive mutations reported here.
The cause of hypouricemia in the remaining two subjects
could not be explained by the mutations reported here.
Whether this implies the existence of another urate trans-
porter or mutations in the regulatory region of SLC22A12
remains to be clarified.
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